Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study
Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Kevin B. Kim(The University of Texas MD Anderson Cancer Center), Sapna P. Patel(JSS Dental College and Hospital), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Mei Liu(Nanchang University), Hyunjin Ryu(The University of Texas MD Anderson Cancer Center), Carol J. Etzel(The University of Texas MD Anderson Cancer Center), Jinhyun Kim(Chungnam National University), Dae Won Kim(Gangneung–Wonju National University), Tong Han Chung(The University of Texas Health Science Center at Houston), Patrick Hwu(Moffitt Cancer Center)
Cited by 9
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594